General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Verb Technology Company Inc (NASDAQ: VERB): Aiming For A Higher Share Price – Stocks Register | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-27 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-15 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -0.65 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.94 | N/A | N/A |
2023-05-22 | 2023-03 | 0 | -1.59 | N/A | N/A |
2023-04-17 | 2022-12 | 0 | -6.4 | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-01-19 | BOND PHILLIP J. | Director | 270.97K | Stock Award(Grant) |
2021-07-13 | CLAYBORNE JEFFREY R | Chief Financial Officer | 1.09M | Conversion of Exercise of derivative security |
2022-01-19 | CRAGUN KENNETH S | Director | 270.97K | Stock Award(Grant) |
2023-06-20 | CUTAIA RORY J | Chief Executive Officer | 191.74K | Stock Award(Grant) |
2023-06-20 | GEISKOPF JAMES P | Director | 35.43K | Stock Award(Grant) |
2022-01-19 | HAMMERSCHMIDT JUDITH LYNNE | Director | 354.67K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Sabby Management, LLC | 129.90K | 140.29K | 2.89% |
2023-06-29 | Blackrock Inc. | 30.63K | 33.08K | 0.68% |
2023-06-29 | Vanguard Group Inc | 23.78K | 25.68K | 0.53% |
2023-06-29 | Geode Capital Management, LLC | 17.28K | 18.66K | 0.38% |
2023-09-29 | Pasadena Private Wealth, LLC | 13.89K | 9.73K | 0.31% |
2023-06-29 | HRT Financial LP | 13.16K | 14.21K | 0.29% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 23.18K | 25.03K | 0.51% |
2023-05-30 | Fidelity Extended Market Index Fund | 8.54K | 12.47K | 0.19% |
2023-05-30 | Fidelity Total Market Index Fund | 4.25K | 6.20K | 0.09% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 3.05K | 2.18K | 0.07% |
2023-05-30 | Fidelity Series Total Market Index Fund | 2.02K | 2.94K | 0.04% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 1.55K | 2.26K | 0.03% |
Split | Date |
---|---|
1 : 40 | 2023-04-19 |
1 : 15 | 2019-02-04 |
Is not enen moving
$MNTS
$MNTS
35 mins ago
1min
Aclarion (ACON.US)
0.400
0.544
+14.38%
+36.00%
Aclarion Shares Are Trading Higher After the Company Announced the Granting of European Patent Titled "Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method (for Diagnosing Pain)."
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy.
STFU moron
Stop spamming DF
"During this quarter, we executed an agreement with United States Air Force Academy ("USAFA") for an initial amount of US$7.3million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. Our partnership with USAFA and the recent agreement execution will enable us to advance this program towards an Investigational New Drug ("IND")," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "Additionally, securing US patent coverage through at least 2039 for ATI-1501, our Metronidazole formulation, is a significant milestone leading up to the anticipated FDA Prescription Drug User Fee ("PDUFA") date on September 23, 2023. We look forward to receiving milestone payments and royalties from our partner, Saptalis Pharmaceuticals LLC ("Saptalis"), in the coming quarters based on their submission and commercialization plans. These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."
$VERB glad I bought in at 26 almost back to 30…..too many paper hands